Newtyn Management’s Keros Therapeutics KROS Stock Holding History

Newtyn Management’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-246,857	Closed	-$3.3M	–	37
2025 Q2	$3.3M	Buy	+246,857	New	+$3.33M	0.5%	29

Other funds holding KROS

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Newtyn Management's KROS Position: Q3 2025 in Review

Newtyn Management sold out of Keros Therapeutics (KROS) in Q3 2025, closing a stake of 246,857 shares — an estimated $3.3M sold.

Newtyn Management first reported a position in KROS in Q2 2025 and held it in 1 quarter. The position peaked at $3.3M in Q2 2025. 155 funds tracked by Wall St. Rank hold KROS as of Q3 2025.

Newtyn Management reported no remaining Keros Therapeutics position as of Q3 2025 after selling out during the quarter.
Newtyn Management sold 246,857 Keros Therapeutics shares in Q3 2025, an estimated $3.3M.
Newtyn Management first reported a position in Keros Therapeutics in Q2 2025 and held it in 1 quarter.
Newtyn Management's Keros Therapeutics position peaked at $3.3M in Q2 2025.
155 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2025.

Based on Newtyn Management's 13F filing for Q3 2025, filed 14 Nov 2025.